Liquidia Corporation
LQDA
Rank in Stocks
#4846
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$34.12
Last synced: 2026-10-19
Market Cap
$3.05B
Change (1 day)
-0.67%
Change (1 year)
39.61%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
Earnings for Liquidia Corporation (LQDA)
Earnings in Jun 2026 TTM: $149.50M
According to Liquidia Corporation latest financial reports the company's current earnings are $149.50M. In 2023 the company made an earning of $-78.50M, a decrease compared to its 2022 earnings that were of $-41.02M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Liquidia Corporation from 2016 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $149.50M | -214.65% |
| 2024 | $-130.39M | 66.10% |
| 2023 | $-78.50M | 91.40% |
| 2022 | $-41.02M | 18.61% |
| 2021 | $-34.58M | -42.14% |
| 2020 | $-59.76M | 25.60% |
| 2019 | $-47.58M | -10.45% |
| 2018 | $-53.14M | 82.26% |
| 2017 | $-29.15M | 82.97% |
| 2016 | $-15.93M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $1.35B | 802.91% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $26.37M | -82.36% |
US
|
